The Carthadex trial.
- Conditions
- Multiple myeloma
- Registration Number
- NL-OMON25987
- Lead Sponsor
- Erasmus MC
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 145
Inclusion Criteria
1. Patients with a confirmed diagnosis of multiple myeloma stage I to III according to the ISS criteria;
2. Age 18-65 years inclusive;
Exclusion Criteria
1. Known intolerance of Thalidomide;
2. Systemic AL amyloidosis;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response (Complete response (CR), very good partial response (VGPR), overall response (OR)):<br /><br>1. After induction prior to HDM/ASCT;<br /><br>2. After HDM/ASCT prior to consolidation treatment;<br /><br>3. At end of consolidation treatment.<br>
- Secondary Outcome Measures
Name Time Method 1. Efficacy and toxicity of induction treatment;<br /><br>2. Efficacy and toxicity of consolidation treatment;<br /><br>3. Feasibility of good quality stem cell harvest;<br /><br>4. Progression-free survival (PFS).<br>